s20098 has been researched along with Drug Withdrawal Symptoms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abulsoud, AI; Fathi, D; Maksimos, MM; Nassar, NN; Rizk, SM; Saad, MA; Senousy, MA | 1 |
| Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F | 1 |
| Owen, RT | 1 |
| Baldwin, DS; Bazire, S; Haddad, PM; McAllister-Williams, RH | 1 |
| Ahokas, A; Albarran, C; Allgulander, C; Olivier, V; Stein, DJ | 1 |
| Kornhuber, J; Maler, JM; Müller, H; Seifert, F; Sperling, W | 1 |
| Burrows, GD; Hindmarch, I; Kennedy, SH; Lejoyeux, M; Montgomery, SA | 1 |
2 review(s) available for s20098 and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Agomelatine: a novel pharmacological approach to treating depression.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Drug Interactions; Humans; Melatonin; Secondary Prevention; Sleep Wake Disorders; Substance Withdrawal Syndrome | 2009 |
The use of antidepressants in clinical practice: focus on agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Contraindications; Depressive Disorder, Major; Drug Interactions; Drug Monitoring; Fluvoxamine; Humans; Liver; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome | 2010 |
3 trial(s) available for s20098 and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Melatonin; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Secondary Prevention; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome; Treatment Outcome | 2009 |
Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
Topics: Acetamides; Adult; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Middle Aged; Personality Inventory; Psychometrics; Risk Factors; Secondary Prevention; Substance Withdrawal Syndrome | 2012 |
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
Topics: Acetamides; Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2004 |
2 other study(ies) available for s20098 and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Agomelatine attenuates alcohol craving and withdrawal symptoms by modulating the Notch1 signaling pathway in rats.
Topics: Acetamides; Alcoholic Beverages; Animals; Anxiety; Behavior, Animal; Biomarkers; Circadian Rhythm; Craving; Hippocampus; Hydrocortisone; Male; Morris Water Maze Test; Neuronal Plasticity; Neurons; Neurotransmitter Agents; Open Field Test; Period Circadian Proteins; Rats, Wistar; Receptor, Notch1; Signal Transduction; Substance Withdrawal Syndrome | 2021 |
Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients.
Topics: Acetamides; Adult; Antidepressive Agents; Behavior, Addictive; Benzodiazepines; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle Aged; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors; Treatment Outcome | 2012 |